02 Why IMYUN
Why IMYUN.
A Large Unmet Need $200B global immuno-oncology market. Most solid tumors still escape and relapse. Checkpoint inhibitors, ADCs, and CAR-Ts cap at 25–50% response. 40–50% of tumors lose the target marker under treatment. $200B market
Compelling Initial Data In a HER2⁺ BCG-primed in vivo model: Significant reduction in tumor volume vs. controls (p<0.00076). 11× increase in active T-cells (CD3⁺CD44⁺) per 10⁵ cells. TME shift from 30.5% exhausted T-cells to 1.1%. Killing confirmed ex vivo by BCG-primed splenocytes (p<0.009). P < 0.00076
Differentiated Mechanism Unlike checkpoint inhibitors, ADCs, or CAR-Ts, ORION™ is designed to: Redirect preexisting pathogen-specific T-cell memory. Deliver multi-epitope coverage across MHC backgrounds. Outlast ADC resistance via epitope spreading. Manufacture cleanly as a recombinant protein. No cell therapy. No viral vectors. No cold chain. First-in-class
Validation Tag. Signal peptides have been clinically tested in humans as T-cell ultimate tags. Mechanism. Pathogen-derived T-cells selectively kill tagged tumor cells in vitro and in vivo. Scaffold. ADC formats with established clinical precedent for safety. In vivo readout. Successful POC in BCG pre-immunized and HER2+ mouse tumor model. Human-validated
Defensible IP Core patent now in the PCT stage and covers ORION™ composition of matter, including 16 cell-surface antigen targets and 11 pathogen-derived signal peptide tags. Freedom-to-operate is supported by 15 years of tag-development work. Filed
Clinical Infrastructure Brown University's Legorreta Cancer Center, via Co-founder and CMO Dr. Wafik El-Deiry, discoverer of p21. Brown University
Expansion path Breast, gastric, ovarian once the wedge is proven. The platform extends to TROP-2, Nectin-4, EGFR, BCMA, and into autoimmune disease, where pharma is currently paying nine figures for CD19-directed assets. 16 targets · 11 tags